Bing

SEARCH HISTORY

Bristol-Myers Squibb Inc.'s stock BMY, +0.86% took an afternoon tumble Friday, to close down 6.6% on heavy volume, as investors expressed disappointment over the drugmaker's updates to studies of its cancer treatment Opdivo. The stock was trading …
Market Watch · ByTomi Kilgore · 5/29/2015
Below are a couple of catalysts that we believe can cause meaningful movement in the company’s stock price. Our current price estimate for Bristol-Myers Squibb stands at $54.70, implying a discount of about 20% to the market. The sales of …
Trefis · 5/27/2015
Progress made by competitors has pulled AstraZeneca down 15 per cent in the past two months, which has erased all of the gains the stock made on Pfizer’s failed bid last year. Bristol-Myers Squibb, Merck and Roche have all shown faster progress than ...
Financial Times · 18 hours ago
AstraZeneca
More from Bing News
Stock prices (NYSE:BMY) rose from $67 per share to $67.59 as news reached investors mid-morning before returning to $66.8 at market close. More than five million trades were reported Thursday afternoon.
The Record-Journal · 6/26/2015
Bristol Myers
Bristol-Myersstock fell more than 7% to $64.24 amid concerns about data released today regarding the use of the drug Opdivo in patient suffering from the most common form of lung cancer. It’s an exciting drug class and analysts see sales for ...
Barron's · ByJohanna Bennett · 5/29/2015
Its largest holding is Bristol-Myers Squibb Company. "This is the largest health care ... it operated 7,822 retail drugstores and 860 health care clinics. The stock recently traded at $105.84 and has a 52-week trading …
USNews · 6/30/2015
Nine patients are hospitalized and one is dead after taking an experimental drug for hepatitis C developed by Bristol-Myers Squibb Company (NYSE: BMY). On Thursday the company announced it had halted development of the drug, aimed at treating lever …
StreetInsider · 8/24/2012
Until just the other day, you know which stock was just as hot? Bristol-Myers Squibb (NYSE:BMY). It's not about the numbers. Last year, the company had sales of $15.9 billion, and net income of $2 billion, or $1.20 per share. It handed out $1.45/share in ...
Seeking Alpha · ByDana Blankenhorn · 6/2/2015
Bristol-Myers investors are paid a 2.45% dividend. Credit Suisse puts a $68 price target on the stock. The consensus target is much lower at $63.41. Shares closed trading Thursday at $60.23. Another top company in the health care sector that makes the …
24/7 Wall ST · 2/6/2015
Critically, however, Credit Suisse sees 2015 as a "catalyst rich period" for Bristol-Myers "in particular." The analysts raised their price target by $2 to $70 and reiterated an Outperform rating. UBS analysts, however, are less bullish on the stock ...
Benzinga · 3/5/2015

Bristol-Myers Squibb

Company
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-M…
Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."
Data from: Wikipedia · Freebase